| Schedule of significant expense categories regularly reviewed by the CODM |
| | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | (in thousands) | | | | | | | | | | | | | Partnership revenue | | $ | — | | $ | 667 | | $ | — | | $ | 1,399 | Product revenue | | | 88 | | | 169 | | | 198 | | | 305 | Expenses: | | | | | | | | | | | | | Cost of product revenues | | | 25 | | | 46 | | | 57 | | | 90 | Non-clinical development costs | | | 3,379 | | | 4,607 | | | 7,429 | | | 9,072 | Clinical development costs | | | 4,960 | | | 2,633 | | | 8,534 | | | 5,575 | Personnel and consulting costs | | | 8,823 | | | 7,002 | | | 17,611 | | | 13,666 | Stock-based compensation | | | 2,505 | | | 3,250 | | | 5,356 | | | 6,215 | Depreciation and amortization expense | | | 96 | | | 81 | | | 186 | | | 164 | Other segment expenses(1) | | | 2,287 | | | 2,544 | | | 2,882 | | | 5,170 | Interest expense (income), net | | | 1,768 | | | 36 | | | 2,589 | | | (130) | Net loss | | $ | (23,755) | | $ | (19,363) | | $ | (44,446) | | $ | (38,118) |
| (1) | Other segment expenses primarily include the gain on the sale of strategic investments as well as general and administrative costs not presented in other line items. |
|